Phase 4
N=44
Resveratrol for Pain Due to Endometriosis
Endometriosis
Bottom Line
View on ClinicalTrials.gov: NCT02475564 ↗Enrolled (actual)
44
Serious AEs
0.0%
Results posted
Aug 2016
Primary outcome: Primary: Pain Scores Measured by VAS (Visual Analog Scale) at Day 42. — 3.2; 3.9 units on a scale — p=0.7
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Placebo (Drug); Resveratrol (Drug)
- Age
- Adult · 20+ yrs
- Sex
- Female
- Sponsor
- Hospital de Clinicas de Porto Alegre
- Primary completion
- Nov 2015
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Pain Scores Measured by VAS (Visual Analog Scale) at Day 42. |
3.2; 3.9 | 0.7 |
| SECONDARY Serum CA125 Levels at 42 Days |
11.7; 13.7 | 0.1 |
| SECONDARY Serum Prolactin Levels at 42 Days |
12; 11.1 | 0.8 |
Summary
This study aims to verify whether the use of 40 mg of resveratrol per day associated with monophasic contraceptive pill (levonorgestrel 0.15mg/ethinyl estradiol 0.03mg) reduces pelvic pain at the end of 2 months of treatment, compared to the use of the pill with placebo.
Eligibility Criteria
Inclusion Criteria
- Endometriosis diagnosed by laparoscopy
Exclusion Criteria
- Known allergy to resveratrol
- Use of gonadotropin or danazol in the last month
Data sourced from ClinicalTrials.gov (NCT02475564). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.